Response-adapted therapy of stage III-IV Hodgkin lymphoma using early interim FDG-PET imaging

eagle-i ID

Resource Type

Properties

1. ClinicalTrials.gov url

   http://www.clinicaltrials.gov/ct2/show/NCT00822120?term=S0816&rank=2

2. Intervention

   Fludeoxyglucose F 18

3. Intervention

   Cyclophosphamide

4. Intervention

   Dacarbazine

5. Intervention

   Doxorubicin hydrochloride

6. Intervention

   Etoposide

7. Intervention

   Prednisone

8. Intervention

   Procarbazine hydrochloride

9. Intervention

   Vinblastine sulfate

10. Intervention

    Vincristine sulfate

11. Additional Topic(s)

    Antineoplastic combined chemotherapy protocols

12. Resource Description

    RATIONALE: G-CSF may help lessen the side effects in patients receiving chemotherapy. Imaging procedures, such as fludeoxyglucose F 18-PET/CT imaging, may help doctors predict how patients will respond to treatment. PURPOSE: This phase II trial is studying fludeoxyglucose F 18-PET/CT imaging to see how well it works in assessing response to combination chemotherapy and allow doctors to plan better additional further treatment in treating patients with stage III or stage IV Hodgkin lymphoma.

13. Contact

    Berenberg, Jeffrey

14. PI

    Berenberg, Jeffrey

15. Topic

    Hodgkin's lymphoma

16. Study Population

    Males and females from ages 18 to 60 years are eligible.

17. Funded by

    SWOG

18. Phase

    Phase 2 clinical trial

19. Performed by

    Clinical Protocol & Data Management Shared Resource